Pharma Stocks Technical Data -- Research on Provectus Biopharma, AstraZeneca, Eli Lilly, and GlaxoSmithKline

LONDON, May 27, 2014 /PRNewswire/ --

On Friday, May 23, 2014, the NASDAQ Composite ended at 4,185.81, up 0.76%, the Dow Jones Industrial Average finished the session at 16,606.27, up 0.38% and the S&P 500 closed at 1,900.53, up 0.42%. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.08% higher at 681.33, and the index has gained 2.63% in the previous one month. Investor-Edge has initiated coverage on the following equities: Provectus Biopharmaceuticals Inc. (NYSE MKT: PVCT), AstraZeneca PLC (NYSE: AZN), Eli Lilly & Co. (NYSE: LLY) and GlaxoSmithKline PLC (NYSE: GSK). Free technical research on PVCT, AZN, LLY and GSK can be downloaded upon signing up at:

http://www.investor-edge.com/3042-register

Shares in Provectus Biopharmaceuticals Inc. finished flat on Friday, closing the session at the previous day's closing price of $2.02. A total of 0.04 million shares were traded, much below its three months average volume of 1.04 million shares. Shares in Provectus Biopharmaceuticals Inc. have fallen by 25.19% in the previous three trading sessions and 10.93% in the last one month. Additionally, the stock has declined 16.18% from the beginning of 2014. The company's shares are trading below their 50-day moving average. The stock's 50-day moving average of $2.42 is above its 200-day moving average of $1.62. Furthermore, Provectus Biopharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of 40.55. Sign up today to read free research on PVCT at:

http://www.investor-edge.com/3042-PVCT-27May2014.pdf

On Friday, shares in AstraZeneca PLC recorded a trading volume of 6.67 million shares, below its three months average volume of 4.90 million shares. The stock finished the day at $72.28, which was 0.17% higher its previous day's closing of $72.16, and registered an intraday range of $72.16 and $73.00. AstraZeneca PLC's stock has advanced 0.11% in the previous three trading sessions, 5.27% in the last one month and 21.74% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages of $69.94 and $60.02, respectively. Moreover, the company's stock has an RSI of 46.09. Sign up today to read free research on AZN at:

http://www.investor-edge.com/3042-AZN-27May2014.pdf

Eli Lilly & Co.'s stock fluctuated between $59.40 and $59.86 before ending Friday's session 0.13% higher at $59.80. The company's stock reported a trading volume of 2.62 million shares, much below its three months average volume of 5.05 million shares. Shares of the company traded at a PE ratio of 16.22. Over the previous three trading sessions and in the last one month, shares in Eli Lilly & Co. have gained 1.94% and 2.22%, respectively. Moreover, the company's stock has surged 17.25% on YTD basis. Eli Lilly & Co.'s stock is trading above its 50-day and 200-day moving averages of $58.99 and $54.05, respectively. Further, the company's shares have an RSI of 55.92. Sign up today to read free research on LLY at:

http://www.investor-edge.com/3042-LLY-27May2014.pdf

GlaxoSmithKline PLC's shares edged 0.56% lower on Friday, closing the day at $54.84. The stock recorded a trading volume of 1.49 million shares, below its three months average volume of 2.65 million shares. The company's stock oscillated between $54.78 and $55.06 during the session. Shares in GlaxoSmithKline PLC have advanced 0.24% in the previous three trading sessions and 2.72% since the start of this year. However, the company's stock has declined 1.65% in the last one month. GlaxoSmithKline PLC's shares are trading above their 50-day and 200-day moving averages of $54.20 and $52.91, respectively. Additionally, the company's stock has an RSI of 49.59. Sign up today to read free research on GSK at:

http://www.investor-edge.com/3042-GSK-27May2014.pdf

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.investor-edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED